Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William Blair – StreetInsider.com
|
Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William Blair
StreetInsider.com William Blair analyst, Tim Lugo, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company announced the FDA had approved an investigational new drug (IND) application for its GALGT2 gene therapy program … Sarepta Therapeutics and Nationwide Children's Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene … |
